Laura Joszt

Patients who took Lundbeck's experimental Alzheimer's drug achieved significant improvement in cognition, according to trial data from the Danish drugmaker.

Ever since Teva Pharmaceuticals released its mixed first quarter earnings report, the company's shares have been on a four-week fall. But there are plenty of brokers still bullish about the stock.

More are considering alternatively fueled vehicles because the cost of gas is getting so high, according to a Consumer Reports survey.

Smaller practices have been leading the way toward e-prescription adoption, and the largest year-over-year growth happened among solo practitioners.

Although oncologists felt left on the sidelines in regards to Accountable Care Organizations, a private insurer and a health system are teaming up to create the first cancer-specific ACO.

The summer is right around the corner and with it people will be flocking to the beach. But just what type of getaway are you looking for?

Unhappy investors in Facebook might get some satisfaction. Regulators have turned their eye on the social networking company as well as lead underwriter Morgan Stanley for the messy stock debut on Friday, May 18.

Decisions on drug approvals can be big news for a company, but it's the investors who get in beforehand who really make out great.

Despite failing to meet its primary endpoint of improving the overall survival rate of patients with non-small cell lung cancer, it wasn't all bad news for Onyx Pharmaceuticals.

Despite months of hype, Facebook's stock debut was more of a whimper than a bang and fraught with difficulties and the news that Morgan Stanley secretly cut revenue forecasts just before.

If you're interested in the hot stocks related to prostate cancer drugs, then you'd be well served to look to urologists, not oncologists.

Dendreon presented strong data on Provenge trials at the American Urological Association, including trial results focusing on Provenge in African Americans.

After a disappointing end to 2011 regarding its lead drug, Exelixis is looking to bounce back with new data in its ASCO abstracts.

In honor of the upcoming ASCO conference, here are the top 10 best-selling cancer drugs based on how much in U.S. sales they brought in last year.

The run up of stocks before the American Society of Clinical Oncology conference has begun if Array BioPharma's stock jump is any indication.

Health care facilities are looking more and more toward temporary doctors to fill the vacancies from full-time physician shortages. Since full-time physicians are often highly stressed, more could appreciate the flexibility that a locum tenens career offers.

Finally, satisfaction with investment firms is nearly equal to pre-recession levels; however, three key areas are lagging.

After losing the patent on antipsychotic Zyprexa in 2011, analysts expected Eli Lilly to have a weak first quarter, but it looks like the company has some upside for 2013.

The market for Alzheimer's drugs might be heating up soon as a number of companies are testing similar drugs to treat the disease. The expectation is that one of these drugs will have a huge payoff.

Brokers are taking the time to reach out to their clients more these days. They're using the technology that's available to them to keep investors confident in investing.

In the U.S., 4% of all retail pharmacies had suspicious or excessive Medicare billing totaling $5.6 billion.

Ariad Pharmaceuticals posted a wider Q1 loss after spending more money to guide its leukemia treatment through late-stage clinical trials and preparing for possible regulatory approval.

Gold fever has been in effect over the last two years, and it doesn't seem to be abating as Americans say that it is their top pick for long-term investments.

Two representatives are presenting a bill to do away with the flawed SGR formula, which dictates the annual cuts to Medicare reimbursement that Congress prevents on a yearly basis.

A new bill introduced in the House would make it mandatory for drug developers to publish all data, even negative results, from cancer clinical studies.

Historically, the months of May to October perform worse than November to April. But those months might be getting dragged down because of a few memorable meltdowns.

To meet the growing need for primary care physicians, medical schools are offering shortened, three-year programs.

In the last year, Zytiga has slowly been eating away at Provenge's target market while Provenge sales stagnate.

So far in 2012 there have been significantly less drug shortages than during the same time frame a year ago.

Despite high electronic health record adoption rates, hospital and health system administrators are mostly less than confident about their ability to meet new EHR standards.